Kenya has administered the first dose of lenacapavir, an HIV prevention drug, to 15,800 people across 15 counties, according to a report by Signs Tv published on Friday, 28 August 2026.
The rollout marks the initial phase of introducing the long-acting injectable to the country's HIV prevention toolkit. Signs Tv reports that the doses were given as part of a broader effort to expand options beyond daily oral PrEP.
Lenacapavir is a twice-yearly injectable that has drawn attention for its potential to improve adherence, as it does not require a daily pill. The Kenyan government's decision to deploy it in 15 counties suggests a targeted approach, likely focusing on areas with high HIV incidence or populations that face barriers to existing prevention methods.
The number of recipients — 15,800 — represents the first wave of what may become a larger national program. Signs Tv did not specify which counties were included or how long the full rollout will take.
Observers will be watching whether the initial distribution stays on schedule and whether follow-up doses are administered on time, as the drug's effectiveness depends on consistent six-month injections.
